secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beta Bionics, Inc. (BBNX)
CIK:        0001674632
Form:       8-K
Filed at:   2026-07-29T20:04:17+00:00
Accession:  0001171843-26-005010
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beta Bionics Q2 net sales up 38% to $32M; gross margin expands 524 bps to 59%
-----------------------------------------------------------------------------

- Net sales $32.0M, up 38% YoY; PBP channel sales surged 153% to $11.6M.
- Gross margin 59.0%, up 524 bps from 53.8% in Q2 2025.
- Net loss $23.4M (negative 73% of sales) vs $16.9M (negative 73%) YoY.
- Adjusted EBITDA negative $17.7M (negative 55% of sales) vs negative $14.5M (negative 63%).
- Cash and investments $225.2M as of June 30, 2026; full year 2026 guidance updated (specifics not provided in excerpt).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674632/000117184326005010/0001171843-26-005010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674632/000117184326005010/f8k_072826.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-005010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer